信迪利单抗联合SOX方案治疗晚期胃癌患者的疗效和安全性分析OA
Efficacy and safety of SOX chemotherapy combined with Sintilimab immunotherapy in treatment of patients with advanced gastric cancer
目的 探讨信迪利单抗联合SOX方案治疗晚期胃癌患者的疗效与安全性.方 法 回顾性收集上海交通大学医学院附属瑞金医院无锡分院 2020 年 1 月至 2024 年 1 月收治的晚期胃癌患者的临床资料,根据治疗方案将患者分为两组,治疗组采用信迪利单抗联合SOX化疗,对照组单用SOX化疗.观察两组患者客观缓解率(ORR)、中位无进展生存期(PFS)、中位总生存期(OS)、生活质量改善、不良反应发生率等情况.结果 共纳入115例晚期胃癌患者,治疗组52例,对照组63例.治疗组ORR显著高于对照组(59.62％vs.38.10％,P<0.05);在PD-L1 CPS≥5 患者中,治疗组ORR显著高于对照组(73.91％vs.37.50％,P<0.05).中位随访时间为 37.0 个月,生存分析显示,治疗组中位PFS(9.3个月 vs.8.1 个月)和中位OS(16.0 个月 vs.12.8 个月)显著优于对照组(P<0.05);在PD-L1 CPS≥5 患者中,治疗组中位PFS(10.2 个月 vs.7.0 个月)和中位OS(17.2 个月 vs.11.0个月)显著优于对照组(P<0.05).治疗组生活质量改善率显著高于对照组(51.92％vs.23.81％,P<0.05).两组间Ⅲ～Ⅳ级毒副反应的发生率未见统计学差异(P>0.05).结 论 在晚期胃癌患者中,信迪利单抗联合SOX方案治疗具有更高的临床疗效,且能显著延长患者的PFS及OS,改善预后,提高生活质量,而不良反应未见明显增加.
Objective To investigate the efficacy and safety of Sintilimab combined with SOX regimen in the treatment of patients with advanced gastric cancer.Methods The clinical data of patients with advanced gastric cancer in Wuxi Branch,Ruijin Hospital,Shanghai Jiaotong University School of Medicine from January 2020 to January 2024 were retrospectively collected.According to the treatment methods,the patients were divided into two groups.The treatment group was treated with Sintilimab combined with SOX regimen,while the control group was treated with SOX regimen alone.The objective response rate(ORR),median progressionfree survival(PFS),median overall survival(OS),incidence of adverse reactions and quality of life were compared between the two groups.Results A total of 115 patients with advanced gastric cancer were included,52 in the treatment group and 63 in the control group.The ORR of the treatment group was significantly higher than that of the control group(59.62％vs.38.10％,P<0.05).Stratified analysis showed that in patients with PD-L1 CPS≥5,the ORR of treatment group was significantly higher than that of control group(73.91％vs.37.50％,P<0.05).The median follow-up time was 37.0 months.Survival analysis showed that the median PFS(9.3 months vs.8.1 months)and the median OS(16.0 months vs.12.8 months)in the treatment group were significantly better than those in the control group(P<0.05).In patients with PD-L1 CPS≥5,the median PFS(10.2 months vs.7.0 months)and median OS(17.2 months vs.11.0 months)in the treatment group were more obvious than those in the control group(P<0.05).The improvement rate of quality of life in the treatment group was significantly higher than that in the control group(51.92％,vs.23.81％,P<0.05).There was no statistical difference in the incidence of grade Ⅲ～Ⅳ side effects between the two groups(P>0.05).Conclusion In patients with advanced gastric cancer,the Sintilimab combined with the SOX regimen has higher clinical efficacy,significantly prolonging the PFS and OS of patients,improving prognosis,and enhancing quality of life.However,adverse effects have not increased significantly.
赵万;颜婧;郭亚平;付庆华;罗琰;张晓娟;陈洋;杨艺;唐新宇
上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)上海交通大学医学院附属瑞金医院无锡分院/无锡市新吴区新瑞医院肿瘤科(江苏 无锡 214111)
医药卫生
胃癌信迪利单抗SOX方案化疗反应性预后
Gastric cancerSintilimabSOX regimenChemotherapy responsePrognosis
《医学新知》 2026 (1)
15-21,7
甘肃省功能基因组与分子诊断重点实验室基金(2021-BYGT005)
评论